Ravendra Garg1, Kienna Mills1, Kevin J H Allen1, Patrick Causey2, Randy W Perron2, Denise Gendron2, Stephen Sanche3, Joan W Berman4, Miroslaw K Gorny5, Ekaterina Dadachova6. 1. College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada. 2. Canadian Nuclear Laboratories, Chalk River, ON, Canada. 3. College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. 4. Albert Einstein College of Medicine, Bronx, NY, USA. 5. Department of Pathology, New York University School of Medicine, New York, NY, USA. 6. College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada. Electronic address: ekaterina.dadachova@usask.ca.
Abstract
BACKGROUND: cART has significantly improved the life expectancy of people living with HIV (PLWH). However, it fails to eliminate the long-lived reservoir of latent HIV-infected cells. Radioimmunotherapy (RIT) relies on antigen-specific monoclonal antibodies (mAbs) for targeted delivery of lethal doses of ionizing radiation to cells. Previously, we have demonstrated that human mAb 2556 against HIV gp41 conjugated with 213Bismuth radioisotope (t1/2 = 46 min, alpha-emitter) selectively killed HIV-infected cells. 225Actinium (t1/2 = 9.92 d, alpha-emitter) and 177Lutetium (t1/2 = 6.7 d, beta-emitter) are two long-lived clinically proven radioisotopes for cancer treatment which might be more effective in killing infected cells systemically and in CNS. METHODS: In this study we have conjugated 2556 mAb with 213Bi, 225Ac and 177Lu, and compared their ability to kill HIV-infected human peripheral blood mononuclear cells (PBMCs) and monocytes. PBMCs and monocytes from healthy donors were infected with HIVp49.5 and treated in vitro with increasing concentrations of 213Bi (4-20 μCi)-, 225Ac (20-100 nCi)- and 177Lu (4-50 μCi)-2556 mAb. RESULTS: After three days post-treatment of infected PBMCs and monocytes, 213Bi- and 177Lu-conjugated 2556 mAb reduced virus production measured by p24 level in a dose-dependent manner, whereas, 225Ac-2556 showed minimal effect. However, seven days post-treatment all three radioisotopes showed significantly more pronounced reduction of virus replication as compared to control labeled mAb with 225Ac-2556 showing the least non-specific killing. CONCLUSION: These results indicate that RIT holds promise as a novel treatment option for the eradication of HIV-infected cells that merits further study in combination with cART and reactivation drugs.
BACKGROUND: cART has significantly improved the life expectancy of people living with HIV (PLWH). However, it fails to eliminate the long-lived reservoir of latent HIV-infected cells. Radioimmunotherapy (RIT) relies on antigen-specific monoclonal antibodies (mAbs) for targeted delivery of lethal doses of ionizing radiation to cells. Previously, we have demonstrated that human mAb 2556 against HIV gp41 conjugated with 213Bismuth radioisotope (t1/2 = 46 min, alpha-emitter) selectively killed HIV-infected cells. 225Actinium (t1/2 = 9.92 d, alpha-emitter) and 177Lutetium (t1/2 = 6.7 d, beta-emitter) are two long-lived clinically proven radioisotopes for cancer treatment which might be more effective in killing infected cells systemically and in CNS. METHODS: In this study we have conjugated 2556 mAb with 213Bi, 225Ac and 177Lu, and compared their ability to kill HIV-infectedhuman peripheral blood mononuclear cells (PBMCs) and monocytes. PBMCs and monocytes from healthy donors were infected with HIVp49.5 and treated in vitro with increasing concentrations of 213Bi (4-20 μCi)-, 225Ac (20-100 nCi)- and 177Lu (4-50 μCi)-2556 mAb. RESULTS: After three days post-treatment of infected PBMCs and monocytes, 213Bi- and 177Lu-conjugated 2556 mAb reduced virus production measured by p24 level in a dose-dependent manner, whereas, 225Ac-2556 showed minimal effect. However, seven days post-treatment all three radioisotopes showed significantly more pronounced reduction of virus replication as compared to control labeled mAb with 225Ac-2556 showing the least non-specific killing. CONCLUSION: These results indicate that RIT holds promise as a novel treatment option for the eradication of HIV-infected cells that merits further study in combination with cART and reactivation drugs.
Authors: Martina Bauer; Michael Goldstein; Markus Christmann; Huong Becker; Daniel Heylmann; Bernd Kaina Journal: Proc Natl Acad Sci U S A Date: 2011-12-12 Impact factor: 11.205
Authors: Ankit Shah; Mohitkumar R Gangwani; Nitish S Chaudhari; Alexy Glazyrin; Hari K Bhat; Anil Kumar Journal: Neurotox Res Date: 2016-06-30 Impact factor: 3.911
Authors: Ekaterina Dadachova; Mahesh C Patel; Sima Toussi; Christos Apostolidis; Alfred Morgenstern; Martin W Brechbiel; Miroslaw K Gorny; Susan Zolla-Pazner; Arturo Casadevall; Harris Goldstein Journal: PLoS Med Date: 2006-11 Impact factor: 11.069
Authors: Wojciech Dawicki; Kevin J H Allen; Rubin Jiao; Mackenzie E Malo; Muath Helal; Mark S Berger; Dale L Ludwig; Ekaterina Dadachova Journal: Oncoimmunology Date: 2019-05-01 Impact factor: 8.110